PureIMS owns exclusive world-wide license rights of Cyclops™, a dry‑powder inhaler for rapid and controlled drug delivery, easy‑to‑use, comfortable, pre‑filled, and disposable, ensuring high dose delivery and a fast onset‑of‑action. Recently the company closed agreements for the application of Cyclops™ in the development of therapeutics for NTM and IPF and for COVID‑19‑vaccination. In addition to partnering programs, PureIMS has a clinical stage in‑house pipeline also open to outlicensing; lead programs are Cyclops™ inhalers for levodopa (PD), epinephrine (anaphylaxis) and colistin (CF and NCFB).
